{"gene":"LPAR2","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":2000,"finding":"LPA2 (EDG4/LP(A2)) couples to multiple G-proteins and mediates LPA-dependent inositol phosphate production, MAPK activation, arachidonic acid release, and inhibition of forskolin-induced cAMP accumulation in neuronal cell lines; LPA2 expression induces cell rounding in neuroblastoma cells.","method":"Retrovirus-mediated heterologous expression in B103 neuroblastoma cells lacking endogenous LPA receptors, followed by functional signaling assays","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1-2 — clean reconstitution system (receptor-null cells), multiple orthogonal signaling readouts","pmids":["11040035"],"is_preprint":false},{"year":2000,"finding":"In human SH-SY5Y neuroblastoma cells, LPA2 (Edg-4) mediates Ca2+ mobilization via production of intracellular sphingosine 1-phosphate (S1P) through sphingosine kinase, independent of Ins(1,4,5)P3 receptor-mediated Ca2+ release, with subsequent interaction between the S1P pathway and IP3 receptors.","method":"Pharmacological inhibition of sphingosine kinase, 45Ca2+ release assays in permeabilized cells, confocal microscopy of Ca2+ puffs, [3H]S1P production measurement","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (metabolite measurement, Ca2+ imaging, permeabilized cell assay) in cells with endogenous Edg-4","pmids":["10954727"],"is_preprint":false},{"year":2002,"finding":"LPA2 acts redundantly with LPA1 to mediate most LPA responses in fibroblasts, including phospholipase C activation, Ca2+ mobilization, adenylyl cyclase activation, proliferation, JNK activation, Akt activation, and stress fiber formation, as demonstrated in lpa1(-/-)/lpa2(-/-) double-knockout mouse embryonic fibroblasts.","method":"Genetic knockout (lpa2-/- and lpa1-/-/lpa2-/- mice), MEF functional assays for PLC, Ca2+, cAMP, proliferation, JNK, Akt, and cytoskeletal responses","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function with multiple orthogonal signaling readouts, replicated across receptor combinations","pmids":["12215548"],"is_preprint":false},{"year":2004,"finding":"LPA2 specifically interacts via its C-terminal PDZ-binding motif with the second PDZ domain of NHERF2, which scaffolds a ternary complex (LPA2–NHERF2–PLC-β3), thereby specifically potentiating LPA-induced PLC-β3 activation and downstream ERK activation leading to COX-2 induction.","method":"Co-immunoprecipitation, PDZ-binding motif mutagenesis, RNA interference of NHERF2 and PLC-β3 isoforms, stable expression in HEK293 cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal interactions confirmed, mutagenesis of binding motif, isoform-specific RNAi, multiple signaling readouts","pmids":["15143197"],"is_preprint":false},{"year":2005,"finding":"In human colon cancer cells, LPA2 activates Akt via Gi-protein and ERK1/2 via PLCβ, and mediates IL-8 synthesis; LPA2 directly interacts with NHERF2, which is required for efficient Akt and ERK1/2 activation.","method":"Pertussis toxin inhibition, PLCβ inhibitor (U-73122), Co-IP of LPA2 and NHERF2, NHERF2 siRNA knockdown, LPA2 siRNA","journal":"American journal of physiology. Cell physiology","confidence":"High","confidence_rationale":"Tier 2 — pharmacological dissection of G-protein coupling, Co-IP, and RNAi in endogenous context","pmids":["15728708"],"is_preprint":false},{"year":2007,"finding":"LPA2 mediates Rho-dependent chemotaxis in breast cancer cells with lower efficacy than LPA1; LPA2 specifically activates RhoA to promote cell migration, as demonstrated by LPA2-specific siRNA and C3 exotransferase treatment in BT-20 cells.","method":"LPA2-specific siRNA, C3 exotransferase (RhoA inhibitor), LPA1 exogenous expression, Ki16425 antagonist, Transwell chemotaxis assay","journal":"American journal of physiology. Cell physiology","confidence":"High","confidence_rationale":"Tier 2 — receptor-specific knockdown combined with RhoA inhibition and rescue experiments","pmids":["17496233"],"is_preprint":false},{"year":2008,"finding":"LPA2 C-terminal tail contains at least two protein interaction motifs mediating PDZ-protein interactions (e.g., NHERF2, MAGI-3) and zinc finger protein interactions (e.g., TRIP6), which regulate the specificity and efficiency of LPA2-mediated signaling.","method":"Review/summary of biochemical protein-protein interaction studies (Co-IP, PDZ binding motif mapping)","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 3 — synthesis review citing multiple interaction studies","pmids":["18501721"],"is_preprint":false},{"year":2009,"finding":"LPA-induced αvβ6 integrin-mediated TGF-β activation in epithelial cells is mediated specifically via LPA2 receptor signaling through Gαq, RhoA, and Rho kinase.","method":"LPA2-specific siRNA knockdown, Gαq pathway inhibition, RhoA and Rho kinase inhibitors, TGF-β bioassay in human bronchial epithelial cells","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — receptor-specific knockdown, pathway dissection with multiple inhibitors, functional TGF-β activation readout","pmids":["19147812"],"is_preprint":false},{"year":2009,"finding":"LPA2 couples to the G12/13/Rho signaling pathway (not Gi) to inhibit EGF-induced migration and invasion of pancreatic cancer cells, contrasting with LPA1-mediated stimulation of migration.","method":"LPA2-specific siRNA, pertussis toxin (Gi inhibitor), LP-105 LPA2-specific agonist, RhoA-dominant negative and C3 toxin, Transwell and Matrigel invasion assays","journal":"Carcinogenesis","confidence":"High","confidence_rationale":"Tier 2 — receptor-specific knockdown, pathway-specific agonist, multiple GTPase inhibitors across multiple cell lines","pmids":["19129242"],"is_preprint":false},{"year":2009,"finding":"LPA2 absence reduces colon tumor formation by attenuating epithelial proliferation and decreasing β-catenin, KLF5, COX-2 expression, and macrophage infiltration via monocyte chemoattractant protein-1 and macrophage migration inhibitory factor.","method":"LPA2 knockout mice in azoxymethane/DSS colitis-associated cancer model, LPA treatment in Apc(min/+) mice, IHC and molecular marker analysis","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with defined mechanistic readouts in validated in vivo cancer model","pmids":["19328876"],"is_preprint":false},{"year":2010,"finding":"MAGI-3 competes with NHERF-2 for binding to LPA2 and PLC-β3: MAGI-3 binding shifts G-protein coupling toward Gα12 (inhibitory signaling), while NHERF-2 promotes Gαq coupling (stimulatory PLC signaling), thereby opposing effects on LPA2-mediated migration, invasion, and NF-κB activation.","method":"Co-IP of LPA2 with MAGI-3, NHERF-2, Gα12, Gαq; MAGI-3 overexpression and knockdown; inositol phosphate production assay; cell migration and invasion assays in HCT116 and SW480","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 — Co-IP, gain- and loss-of-function, multiple functional readouts, competition mechanism demonstrated","pmids":["21134377"],"is_preprint":false},{"year":2011,"finding":"LPA stimulates DRA (SLC26A3) gene transcription through the LPA2 receptor via a PI3K/AKT and c-Fos-dependent pathway acting on the -1183/-790 region of the DRA promoter.","method":"LPA2 siRNA knockdown, PI3K inhibitor, DRA promoter deletion constructs/reporter assays, EMSA, c-Fos overexpression and siRNA in Caco-2 cells","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"High","confidence_rationale":"Tier 2 — receptor-specific knockdown, promoter mapping, EMSA, transcription factor overexpression/knockdown","pmids":["22159277"],"is_preprint":false},{"year":2012,"finding":"LPA2 mediates proximal tubule cell secretion of PDGF-B and CTGF through Gαq, Rho/Rho-kinase, and αvβ6 integrin-dependent transactivation of latent TGF-β, which then activates SMAD signaling to upregulate these profibrotic cytokines.","method":"LPA2 siRNA, Gαq inhibition, Rho/ROCK inhibitors, αvβ6 integrin blocking antibody, TGF-β bioassays, SMAD signaling analysis, ischemia-reperfusion injury rat model","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — receptor-specific knockdown, multi-level pathway inhibition, in vitro and in vivo concordance","pmids":["22885106"],"is_preprint":false},{"year":2012,"finding":"LPA2 activation promotes an antiapoptotic signaling complex comprising LPA2, NHERF2, and TRIP6 (thyroid receptor interacting protein 6); non-lipid LPA2-specific agonist GRI977143 assembles this complex and activates ERK1/2 prosurvival signaling, reducing caspase activation and DNA fragmentation.","method":"Co-IP of LPA2–NHERF2–TRIP6 complex, MEF cells from LPA1&2-DKO reconstituted with LPA2, caspase activity assays, PARP cleavage, DNA fragmentation, ERK1/2 phosphorylation","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 2 — reconstituted receptor-null system, complex formation by Co-IP, multiple apoptosis readouts, LPA2-specific agonist","pmids":["22968304"],"is_preprint":false},{"year":2014,"finding":"LPA2 mediates collective cell migration of neural crest cells in vivo by promoting N-cadherin internalization downstream of LPA, reducing cell-cell adhesion and increasing tissue fluidity to allow a solid-to-fluid-like transition while maintaining collective behavior.","method":"In vivo neural crest imaging (Xenopus), LPA2 inhibition/knockdown, N-cadherin trafficking assays, rheological analysis of tissue fluidity","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with defined cellular mechanism (cadherin internalization) and biophysical readout in vivo","pmids":["25002680"],"is_preprint":false},{"year":2014,"finding":"LPA2 forms spatiotemporally restricted, asymmetric macromolecular complexes via PDZ motif-mediated interactions at the leading edge of chemotacting fibroblasts, triggering localized Ca2+ puff gradients that govern gradient sensing and directional migration toward LPA.","method":"Single-particle tracking of LPA2 mobility, PDZ motif mutagenesis, Ca2+ imaging, directional migration assays in fibroblasts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — single-particle tracking + mutagenesis + functional Ca2+ and migration readouts","pmids":["25542932"],"is_preprint":false},{"year":2014,"finding":"Crystal structure of NHERF2 PDZ1 domain in complex with the C-terminal LPA2 peptide reveals that binding specificity is achieved through hydrogen bonds and hydrophobic contacts with the last four LPA2 residues, and identifies a small surface pocket adjacent to the binding site.","method":"X-ray crystallography of NHERF2 PDZ1–LPA2 C-terminal peptide complex","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with atomic resolution of the interaction interface","pmids":["24613836"],"is_preprint":false},{"year":2015,"finding":"The autotaxin-LPA2 axis is upregulated by γ-irradiation via an ATM/NF-κB-dependent mechanism; LPA2 activation accelerates DNA damage repair (resolution of γ-H2AX) through ERK1/2 and PI3K/AKT pathways, and the C-terminus of LPA2 (C311A/C314A/L351A mutation) is required for this effect.","method":"qRT-PCR, NF-κB site mutagenesis in lpa2 promoter, ATM/ATR kinase inhibitor (CGK-733), γ-H2AX kinetics in LPA2-reconstituted MEF cells, pertussis toxin, C-terminal LPA2 mutagenesis, Lpar2 KO mice irradiation model","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 1-2 — promoter mutagenesis, receptor mutagenesis, reconstituted system, in vivo KO confirmation","pmids":["26027517"],"is_preprint":false},{"year":2016,"finding":"TRIP6 functions as a positive regulator of LPA2-induced NF-κB and JNK signaling by directly binding and activating the E3 ligase TRAF6 upon LPA stimulation; TRIP6 antagonizes recruitment of deubiquitinases A20 and CYLD to TRAF6, sustaining its E3 ligase activity. Conversely, TRAF6 promotes TRIP6 phosphorylation by c-Src and its binding to NF-κB p65.","method":"Co-IP of TRIP6–TRAF6–LPA2, TRIP6 shRNA and CRISPR/sgRNA knockdown, TRAF6 siRNA, overexpression assays, NF-κB and JNK/p38 activation assays in ovarian cancer cells","journal":"Cell discovery","confidence":"High","confidence_rationale":"Tier 2 — Co-IP of complex components, multiple loss-of-function approaches, mechanistic dissection of ubiquitin pathway","pmids":["27134758"],"is_preprint":false},{"year":2017,"finding":"LPA2 forms a macromolecular complex with CFTR and NHERF2 at the apical plasma membrane of airway and gut epithelial cells; disruption of the PDZ-mediated NHERF2–LPA2 interaction abolishes the LPA inhibitory effect on CFTR Cl- channel activity.","method":"Co-IP, PDZ motif disruption, CFTR channel activity measurements (reviewed with prior functional data)","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 3 — review synthesizing prior Co-IP and functional data from multiple papers","pmids":["28869532"],"is_preprint":false},{"year":2018,"finding":"LPA2 mediates LPA-induced ovarian cancer cell migration via phosphorylation of ERM (ezrin/radixin/moesin) proteins at their C-termini through the Gα12/13/RhoA pathway; gene silencing of LPA2 or expression of dominant-negative ezrin completely abolishes LPA-induced migration.","method":"LPA receptor siRNA knockdown, Gα pathway inhibitors, ERM phosphorylation western blot, dominant-negative ezrin-T567A overexpression, Transwell migration assay in OVCAR-3 cells","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 2 — receptor-specific knockdown, pathway dissection, dominant-negative functional rescue","pmids":["29329782"],"is_preprint":false},{"year":2020,"finding":"LPA2 receptor agonism reduces γ-irradiation-induced disruption of colonic epithelial tight junction proteins via a Rho-kinase-dependent mechanism, protecting mucosal barrier function and reducing endotoxemia; Lpar2-/- mice show more severe TJ disruption after irradiation than wild-type mice.","method":"Lpar2 KO mice, LPA2 agonist RP1 (Radioprotectin-1), ROCK inhibitor, immunofluorescence of TJ proteins, mucosal permeability (inulin), plasma LPS measurement, actin cytoskeleton imaging","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 — genetic KO and pharmacological agonism, pathway inhibition, multiple functional readouts in vitro and in vivo","pmids":["32654268"],"is_preprint":false},{"year":2021,"finding":"LPA2 receptor activation promotes endothelial cell proliferation through PI3K-Akt/PLC-Raf1-Erk signaling and enhances tube formation via PKD1-CD36 signaling; endothelial-specific LPA2 knockout phenocopies global knockout in cardiac ischemia, establishing LPA2 as the relevant LPA receptor in cardiac endothelial cells after MI.","method":"Global and endothelial-specific Lpar2 KO mice, adenovirus-mediated Lpar2 overexpression, pharmacological LPA2 activation, MI models (adult and neonatal), PI3K/Akt/PLC/ERK pathway inhibition, tube formation assays","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 — cell type-specific KO phenocopy, adenoviral rescue, multiple signaling pathway readouts, in vivo and in vitro concordance","pmids":["35920162"],"is_preprint":false},{"year":2021,"finding":"Proximal tubule LPA1 and LPA2 receptors use divergent signaling pathways (LPA2 via Gαq-αvβ6-TGF-β1/SMAD; LPA1 via EGFR-ERK1/2-AP-1) that additively increase PDGF-B and CTGF production; autotaxin inhibition suppresses both pathways.","method":"Pathway-specific inhibitors for each arm, autotaxin inhibitor, dual receptor knockdown/inhibition, SMAD and ERK signaling readouts in proximal tubule cells and IRI kidneys","journal":"American journal of physiology. Renal physiology","confidence":"High","confidence_rationale":"Tier 2 — pathway-specific dissection of two receptors with convergent functional output, in vitro and in vivo concordance","pmids":["33427061"],"is_preprint":false},{"year":2022,"finding":"Endothelial LPA2 protects vascular barrier function in septic ALI through the PLC-PKC-FAK signaling pathway, maintaining tight junction (ZO-1, claudin-5) and adherens junction (VE-cadherin) protein expression.","method":"Lpar2 KO mice (LPS-induced sepsis model), DBIBB LPA2 agonist, transendothelial electrical resistance (TEER), Evans blue dye permeability, Western blot of junction proteins, PLC/PKC/FAK pathway analysis in MLMECs","journal":"Journal of inflammation research","confidence":"High","confidence_rationale":"Tier 2 — genetic KO and pharmacological agonism, defined signaling pathway, multiple functional endothelial barrier readouts","pmids":["38026263"],"is_preprint":false},{"year":2025,"finding":"LPA2 interacts via its PDZ-binding motif in its carboxyl terminus with Dishevelled proteins Dvl2 and Dvl3 in colon cancer cells, co-activating canonical Wnt/β-catenin signaling (S552 and S675 phosphorylation, β-catenin transcriptional activity) in a non-additive manner with Wnt-3a; mutation of the LPA2 PDZ motif (LPA2-PDZminus) disrupts this interaction and impairs canonical Wnt signaling activation.","method":"Co-immunoprecipitation of LPA2 with Dvl2/Dvl3, LPA2-PDZminus mutant expression, β-catenin reporter assay, phospho-β-catenin Western blot, cell migration and proliferation assays","journal":"Cellular signalling","confidence":"High","confidence_rationale":"Tier 2 — Co-IP demonstrating physical interaction, PDZ motif mutagenesis with functional consequence on Wnt signaling","pmids":["41418976"],"is_preprint":false},{"year":2015,"finding":"LPA2 receptor phosphorylation requires higher concentrations of LPA or PKC activators than LPA1/LPA3, and its internalization is less intense; homologous desensitization of LPA2 occurs independently of PKC. LPA2-mediated ERK1/2 phosphorylation involves EGF receptor transactivation.","method":"Stably expressed LPA1, LPA2, LPA3 in C9 cells; phorbol ester (PMA) and bisindolylmaleimide I treatment; PKC down-regulation; EGFR tyrosine kinase inhibitor; intracellular Ca2+ assay; ERK phosphorylation","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pharmacological tools in heterologous expression system, but single lab with one system","pmids":["26473723"],"is_preprint":false},{"year":2020,"finding":"LPA2 signaling in macrophages mediates ATX/LPA-induced pro-inflammatory cytokine production; LPA2 gene silencing in RAW264.7 macrophages reduces inflammatory cytokine output, and adenoviral lpa2 shRNA delivery ameliorates DSS-induced colitis in mice.","method":"LPA2 siRNA in RAW264.7 and BMDM, adenoviral lpa2 shRNA in DSS colitis mouse model, cytokine ELISA, qRT-PCR of LPA2 expression","journal":"Journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — receptor-specific knockdown in vitro and in vivo, but mechanistic pathway detail limited","pmids":["33128578"],"is_preprint":false},{"year":2019,"finding":"LPA2 mediates LPA-induced migration and invasion of gastric cancer cells through activation of Notch1 signaling and PI3K/AKT phosphorylation; LPA2 physically interacts with Notch1 as shown by co-immunoprecipitation.","method":"LPA2 and Notch1 siRNA knockdown, Transwell migration/invasion assays, immunoprecipitation of LPA2-Notch1 complex, EMT marker analysis in SGC-7901 cells","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 3 — single Co-IP plus functional knockdown, but novel interaction without structural validation","pmids":["31115486"],"is_preprint":false},{"year":2021,"finding":"LPA2 interacts with GPR55 in live cells (BRET analysis); co-activation of LPA2 and GPR55 leads to co-internalization, synergistic reduction in intracellular cAMP, and synergistic promotion of cell proliferation and cancer gene expression.","method":"BRET (bioluminescence resonance energy transfer) in live cells, co-internalization imaging, cAMP measurement, cell proliferation assay","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 — BRET demonstrates physical proximity in live cells, functional co-activation readouts, but single lab study","pmids":["33959968"],"is_preprint":false}],"current_model":"LPAR2 is a Gαi-, Gαq-, and Gα12/13-coupling GPCR for lysophosphatidic acid whose signaling specificity and efficiency are determined by a C-terminal PDZ-binding motif that scaffolds context-dependent macromolecular complexes (with NHERF2–PLC-β3, MAGI-3, TRIP6–TRAF6, and Dvl2/Dvl3), activating downstream pathways including PLC-β/Ca2+/IP3, PI3K-Akt, ERK1/2, RhoA, and NF-κB to mediate cell survival, migration, cytoskeletal reorganization, epithelial barrier maintenance, TGF-β transactivation via αvβ6 integrin, DNA damage repair, and Wnt signaling, while also acting as a radioprotective and anti-apoptotic receptor whose lpa2 gene is itself a DNA-damage-response gene transcriptionally upregulated by ATM via NF-κB."},"narrative":{"teleology":[{"year":2000,"claim":"Establishing that LPA2 is a functional multi-pathway GPCR resolved which signaling outputs this receptor activates, demonstrating coupling to PLC/IP production, MAPK, arachidonic acid release, cAMP inhibition, and Ca²⁺ mobilization.","evidence":"Heterologous expression in receptor-null B103 neuroblastoma cells and Ca²⁺/sphingosine kinase assays in SH-SY5Y cells","pmids":["11040035","10954727"],"confidence":"High","gaps":["Relative contribution of individual G-protein subtypes not resolved","No structural information on receptor-G-protein coupling"]},{"year":2002,"claim":"Genetic ablation of Lpar1 and Lpar2 in mouse fibroblasts demonstrated functional redundancy between LPA1 and LPA2 for most LPA responses, defining LPA2 as necessary for full LPA signaling when LPA1 is absent.","evidence":"Lpa1⁻/⁻/lpa2⁻/⁻ double-knockout MEFs with multiple signaling readouts","pmids":["12215548"],"confidence":"High","gaps":["Receptor-specific versus shared downstream effectors not delineated","In vivo phenotype of lpa2 single knockout not yet characterized"]},{"year":2004,"claim":"Discovery of the NHERF2–LPA2–PLC-β3 ternary complex identified the PDZ-binding motif as the molecular determinant of LPA2 signaling specificity, explaining how a broadly coupled GPCR achieves selective effector activation.","evidence":"Co-IP, PDZ motif mutagenesis, and isoform-specific RNAi in HEK293 cells","pmids":["15143197"],"confidence":"High","gaps":["Stoichiometry and dynamics of the ternary complex unknown","Whether other PDZ scaffold proteins compete for this motif not yet tested"]},{"year":2007,"claim":"Receptor-specific knockdown established that LPA2 activates RhoA to drive breast cancer cell chemotaxis, distinguishing its migration mechanism from LPA1 and revealing G12/13-RhoA as an LPA2-selective pathway arm.","evidence":"LPA2 siRNA, C3 exotransferase, and Transwell assays in BT-20 cells","pmids":["17496233"],"confidence":"High","gaps":["RhoGEF linking LPA2 to RhoA not identified","Context-dependence of LPA2 promoting versus inhibiting migration not explained"]},{"year":2009,"claim":"Three contemporaneous studies revealed LPA2's diverse in vivo roles: Gαq/RhoA-dependent TGF-β transactivation via αvβ6 integrin in epithelia, G12/13-dependent suppression of EGF-induced migration in pancreatic cancer, and promotion of colon tumorigenesis through β-catenin/COX-2 in knockout mice.","evidence":"Receptor-specific siRNA with pathway inhibitors in bronchial/pancreatic cells; Lpar2⁻/⁻ mice in AOM/DSS colon cancer model","pmids":["19147812","19129242","19328876"],"confidence":"High","gaps":["How LPA2 promotes migration in one context but inhibits it in another remains mechanistically unresolved","Direct targets linking LPA2 to β-catenin stabilization not identified"]},{"year":2010,"claim":"The discovery that MAGI-3 competes with NHERF2 for the LPA2 PDZ motif and shifts G-protein coupling from Gαq toward Gα12 established a scaffold-switching model for bidirectional regulation of LPA2 signaling.","evidence":"Co-IP competition experiments, MAGI-3 overexpression/knockdown with signaling readouts in colon cancer cells","pmids":["21134377"],"confidence":"High","gaps":["What determines the relative abundance of MAGI-3 versus NHERF2 at the receptor in different tissues","Whether scaffold switching occurs dynamically in real time"]},{"year":2012,"claim":"Identification of the LPA2–NHERF2–TRIP6 antiapoptotic complex and demonstration of LPA2-mediated TGF-β/SMAD-dependent fibrotic signaling in kidney established dual pro-survival and pro-fibrotic effector arms downstream of LPA2.","evidence":"Co-IP in reconstituted LPA1/2-DKO MEFs with LPA2-specific agonist GRI977143; pathway dissection with ROCK/Gαq inhibitors in proximal tubule cells and IRI rat model","pmids":["22968304","22885106"],"confidence":"High","gaps":["How TRIP6 is recruited to LPA2 (direct or NHERF2-bridged) not fully resolved","Whether the antiapoptotic complex operates in non-epithelial cell types unknown"]},{"year":2014,"claim":"Single-particle tracking and in vivo neural crest imaging revealed that LPA2 PDZ-dependent complexes are spatially polarized at the leading edge, generating asymmetric Ca²⁺ gradients for chemotaxis and driving N-cadherin internalization for collective cell migration.","evidence":"Single-particle tracking with PDZ mutagenesis in fibroblasts; LPA2 knockdown in Xenopus neural crest with rheological analysis","pmids":["25542932","25002680"],"confidence":"High","gaps":["Identity of the PDZ scaffold at the leading edge not determined","How N-cadherin internalization is mechanistically linked to LPA2 downstream signaling not established"]},{"year":2014,"claim":"Crystal structure of NHERF2-PDZ1 bound to the LPA2 C-terminal peptide provided atomic-level understanding of the specificity determinants, revealing hydrogen-bonding and hydrophobic contacts and a druggable surface pocket.","evidence":"X-ray crystallography of NHERF2 PDZ1–LPA2 peptide complex","pmids":["24613836"],"confidence":"High","gaps":["No full-length LPA2 structure in complex with NHERF2","Whether the adjacent pocket is functionally exploitable not tested"]},{"year":2015,"claim":"Demonstration that LPA2 is a DNA damage-response gene transcriptionally induced by γ-irradiation through ATM/NF-κB, and that LPA2 activation accelerates γ-H2AX resolution via ERK/PI3K-Akt, established a feed-forward radioprotective circuit dependent on the C-terminal interaction motif.","evidence":"LPA2 promoter NF-κB site mutagenesis, ATM inhibitor, γ-H2AX kinetics in LPA2-reconstituted MEFs, Lpar2 KO mice irradiation","pmids":["26027517"],"confidence":"High","gaps":["Direct DNA repair effectors downstream of ERK/Akt in this context not identified","Whether this radioprotective mechanism operates in non-intestinal tissues not tested"]},{"year":2016,"claim":"Mechanistic dissection of the TRIP6–TRAF6 axis showed TRIP6 sustains LPA2-induced NF-κB signaling by activating TRAF6 E3 ligase activity and antagonizing deubiquitinases A20/CYLD, providing the molecular logic for how the LPA2 C-terminal scaffold drives inflammatory gene expression.","evidence":"Co-IP, CRISPR knockout, and shRNA knockdown of TRIP6/TRAF6 with NF-κB/JNK readouts in ovarian cancer cells","pmids":["27134758"],"confidence":"High","gaps":["Ubiquitin chain types on TRAF6 in LPA2 context not defined","Whether TRIP6-TRAF6 engagement is unique to LPA2 or shared with other GPCRs"]},{"year":2020,"claim":"Pharmacological agonism and genetic ablation of LPA2 established its role in maintaining epithelial tight junctions after irradiation via Rho-kinase, and in macrophage-mediated inflammation during colitis, broadening its barrier-protective and immunomodulatory functions.","evidence":"Lpar2 KO mice with RP1 agonist in irradiation model; LPA2 siRNA in macrophages and adenoviral shRNA in DSS colitis model","pmids":["32654268","33128578"],"confidence":"High","gaps":["Which tight junction proteins are direct versus indirect targets of Rho-kinase in this context","Macrophage-specific signaling pathway downstream of LPA2 not detailed"]},{"year":2021,"claim":"Endothelial-specific Lpar2 knockout phenocopied global knockout in cardiac ischemia, establishing LPA2 as the functionally relevant LPA receptor in cardiac endothelium where it drives angiogenesis through PI3K-Akt/PLC-Raf1-Erk and PKD1-CD36 pathways.","evidence":"Endothelial-specific and global Lpar2 KO, adenoviral rescue, MI models in adult and neonatal mice","pmids":["35920162"],"confidence":"High","gaps":["How PKD1-CD36 signaling mechanistically connects to tube formation not defined","Whether LPA2 agonism is therapeutic post-MI not tested in preclinical intervention studies"]},{"year":2022,"claim":"LPA2 was shown to protect endothelial barrier function in sepsis through PLC-PKC-FAK signaling that maintains tight and adherens junction proteins, extending the barrier-protective role from epithelial to endothelial contexts.","evidence":"Lpar2 KO mice in LPS-sepsis model, DBIBB agonist, TEER, Evans blue permeability, junction protein analysis in MLMECs","pmids":["38026263"],"confidence":"High","gaps":["Whether FAK is directly phosphorylated by PKC or through an intermediate kinase","Endothelial scaffold complex identity (NHERF2 or other) not determined"]},{"year":2025,"claim":"Discovery of a PDZ-dependent LPA2–Dvl2/Dvl3 interaction that co-activates canonical Wnt/β-catenin signaling provided a molecular mechanism for the earlier observation that LPA2 loss reduces β-catenin in colon tumors.","evidence":"Co-IP of LPA2 with Dvl2/Dvl3, PDZ-minus mutant, β-catenin reporter and phospho-β-catenin analysis in colon cancer cells","pmids":["41418976"],"confidence":"High","gaps":["Whether LPA2-Dvl interaction occurs through direct PDZ-PDZ binding or requires a bridging scaffold","Functional consequence of LPA2-Wnt crosstalk in vivo not tested"]},{"year":null,"claim":"A full-length structure of LPA2 in complex with its C-terminal scaffolding partners is lacking, and the rules governing scaffold selection (NHERF2 vs MAGI-3 vs TRIP6 vs Dvl) in different tissue contexts remain undefined.","evidence":"","pmids":[],"confidence":"High","gaps":["No full-length LPA2 cryo-EM or crystal structure with scaffold bound","Tissue-specific determinants of scaffold partner selection unknown","Therapeutic window for LPA2 agonism (radioprotection/barrier) versus antagonism (cancer) not delineated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,2]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,2]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[15,19,24]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,3,4,7,8,10,17,20,22,24,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,9,28]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[17]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[13,17]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[14,21,24]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[14]}],"complexes":["LPA2–NHERF2–PLC-β3","LPA2–NHERF2–TRIP6","TRIP6–TRAF6"],"partners":["NHERF2","MAGI-3","TRIP6","TRAF6","DVL2","DVL3","PLC-Β3","CFTR"],"other_free_text":[]},"mechanistic_narrative":"LPAR2 (LPA2/EDG4) is a lysophosphatidic acid receptor that couples to Gαi, Gαq, and Gα12/13 to activate PLC-β/Ca²⁺, PI3K-Akt, ERK1/2, RhoA, NF-κB, and Wnt/β-catenin signaling, thereby regulating cell survival, proliferation, migration, cytoskeletal dynamics, and epithelial/endothelial barrier integrity [PMID:11040035, PMID:12215548, PMID:25002680, PMID:32654268, PMID:38026263]. Signaling specificity is determined by a C-terminal PDZ-binding motif that recruits context-dependent scaffolding partners — NHERF2 promotes Gαq/PLC-β3 coupling and ERK activation, MAGI-3 redirects coupling toward Gα12 to oppose NHERF2-driven responses, and TRIP6 activates TRAF6-dependent NF-κB signaling — while interaction with Dvl2/Dvl3 co-activates canonical Wnt signaling [PMID:15143197, PMID:21134377, PMID:27134758, PMID:41418976]. LPA2 also functions as a radioprotective receptor: its gene is transcriptionally upregulated by γ-irradiation via ATM/NF-κB, and its activation accelerates DNA damage repair and preserves tight junction integrity through Rho-kinase-dependent mechanisms [PMID:26027517, PMID:32654268]. In vivo, LPA2 loss reduces colitis-associated colon tumorigenesis by attenuating β-catenin, COX-2, and macrophage infiltration, while endothelial-specific deletion impairs cardiac angiogenesis after myocardial infarction [PMID:19328876, PMID:35920162]."},"prefetch_data":{"uniprot":{"accession":"Q9HBW0","full_name":"Lysophosphatidic acid receptor 2","aliases":["Lysophosphatidic acid receptor Edg-4"],"length_aa":348,"mass_kda":38.7,"function":"Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. Seems to be coupled to the G(i)/G(o), G(12)/G(13), and G(q) families of heteromeric G proteins. Plays a key role in phospholipase C-beta (PLC-beta) signaling pathway. Stimulates phospholipase C (PLC) activity in a manner that is independent of RALA activation","subcellular_location":"Cell surface; Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q9HBW0/entry"},"depmap":{"release":"DepMap","has_data":false,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LPAR2"},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LPAR2","total_profiled":1310},"omim":[{"mim_id":"605110","title":"LYSOPHOSPHATIDIC ACID RECEPTOR 2; LPAR2","url":"https://www.omim.org/entry/605110"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":74.0}],"url":"https://www.proteinatlas.org/search/LPAR2"},"hgnc":{"alias_symbol":["EDG-4","LPA2"],"prev_symbol":["EDG4"]},"alphafold":{"accession":"Q9HBW0","domains":[{"cath_id":"1.20.1070.10","chopping":"20-309","consensus_level":"medium","plddt":91.1647,"start":20,"end":309}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HBW0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HBW0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9HBW0-F1-predicted_aligned_error_v6.png","plddt_mean":85.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LPAR2","jax_strain_url":"https://www.jax.org/strain/search?query=LPAR2"},"sequence":{"accession":"Q9HBW0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9HBW0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9HBW0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9HBW0"}},"corpus_meta":[{"pmid":"12215548","id":"PMC_12215548","title":"Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2).","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12215548","citation_count":262,"is_preprint":false},{"pmid":"19147812","id":"PMC_19147812","title":"Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q).","date":"2009","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19147812","citation_count":176,"is_preprint":false},{"pmid":"11040035","id":"PMC_11040035","title":"Functional comparisons of the lysophosphatidic acid receptors, LP(A1)/VZG-1/EDG-2, LP(A2)/EDG-4, and LP(A3)/EDG-7 in neuronal cell lines using a retrovirus expression system.","date":"2000","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11040035","citation_count":164,"is_preprint":false},{"pmid":"12586875","id":"PMC_12586875","title":"The maize low-phytic acid mutant lpa2 is caused by mutation in an inositol phosphate kinase gene.","date":"2003","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12586875","citation_count":123,"is_preprint":false},{"pmid":"19328876","id":"PMC_19328876","title":"The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer.","date":"2009","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19328876","citation_count":108,"is_preprint":false},{"pmid":"25002680","id":"PMC_25002680","title":"In vivo collective cell migration requires an LPAR2-dependent increase in tissue fluidity.","date":"2014","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25002680","citation_count":106,"is_preprint":false},{"pmid":"15728708","id":"PMC_15728708","title":"LPA2 receptor mediates mitogenic signals in human colon cancer cells.","date":"2005","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15728708","citation_count":96,"is_preprint":false},{"pmid":"22885106","id":"PMC_22885106","title":"Lysophosphatidic acid increases proximal tubule cell secretion of profibrotic cytokines PDGF-B and CTGF through LPA2- and Gαq-mediated Rho and αvβ6 integrin-dependent activation of TGF-β.","date":"2012","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22885106","citation_count":83,"is_preprint":false},{"pmid":"11291053","id":"PMC_11291053","title":"Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11291053","citation_count":78,"is_preprint":false},{"pmid":"17496233","id":"PMC_17496233","title":"LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells.","date":"2007","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17496233","citation_count":77,"is_preprint":false},{"pmid":"15143197","id":"PMC_15143197","title":"NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15143197","citation_count":75,"is_preprint":false},{"pmid":"10954727","id":"PMC_10954727","title":"Lysophosphatidic acid-induced Ca2+ mobilization requires intracellular sphingosine 1-phosphate production. Potential involvement of endogenous EDG-4 receptors.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10954727","citation_count":65,"is_preprint":false},{"pmid":"17601825","id":"PMC_17601825","title":"LPA2 is required for efficient assembly of photosystem II in Arabidopsis thaliana.","date":"2007","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/17601825","citation_count":64,"is_preprint":false},{"pmid":"10729222","id":"PMC_10729222","title":"Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA.","date":"2000","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10729222","citation_count":59,"is_preprint":false},{"pmid":"22968304","id":"PMC_22968304","title":"Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions.","date":"2012","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22968304","citation_count":56,"is_preprint":false},{"pmid":"19129242","id":"PMC_19129242","title":"LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.","date":"2009","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/19129242","citation_count":56,"is_preprint":false},{"pmid":"21134377","id":"PMC_21134377","title":"MAGI-3 competes with NHERF-2 to negatively regulate LPA2 receptor signaling in colon cancer cells.","date":"2010","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/21134377","citation_count":53,"is_preprint":false},{"pmid":"35920162","id":"PMC_35920162","title":"LPA2 Contributes to Vascular Endothelium Homeostasis and Cardiac Remodeling After Myocardial Infarction.","date":"2022","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/35920162","citation_count":51,"is_preprint":false},{"pmid":"19930563","id":"PMC_19930563","title":"Role of lysophosphatidic acid receptor LPA2 in the development of allergic airway inflammation in a murine model of asthma.","date":"2009","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/19930563","citation_count":51,"is_preprint":false},{"pmid":"14712217","id":"PMC_14712217","title":"Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2).","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14712217","citation_count":47,"is_preprint":false},{"pmid":"22427635","id":"PMC_22427635","title":"Lpa2 is a negative regulator of both dendritic cell activation and murine models of allergic lung inflammation.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22427635","citation_count":46,"is_preprint":false},{"pmid":"25003200","id":"PMC_25003200","title":"Regulation of T cell motility in vitro and in vivo by LPA and LPA2.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25003200","citation_count":46,"is_preprint":false},{"pmid":"30847983","id":"PMC_30847983","title":"LPA1 , LPA2 , LPA4 , and LPA6 receptor expression during mouse brain development.","date":"2019","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/30847983","citation_count":43,"is_preprint":false},{"pmid":"26027517","id":"PMC_26027517","title":"The autotaxin-LPA2 GPCR axis is modulated by γ-irradiation and facilitates DNA damage repair.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26027517","citation_count":42,"is_preprint":false},{"pmid":"29329782","id":"PMC_29329782","title":"LPA-induced migration of ovarian cancer cells requires activation of ERM proteins via LPA1 and LPA2.","date":"2018","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/29329782","citation_count":38,"is_preprint":false},{"pmid":"20605914","id":"PMC_20605914","title":"Cooperation of LPA3 and LPA2 is essential for photosystem II assembly in Arabidopsis.","date":"2010","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20605914","citation_count":37,"is_preprint":false},{"pmid":"25619933","id":"PMC_25619933","title":"Combined mitigation of the gastrointestinal and hematopoietic acute radiation syndromes by an LPA2 receptor-specific nonlipid agonist.","date":"2015","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/25619933","citation_count":34,"is_preprint":false},{"pmid":"18178086","id":"PMC_18178086","title":"Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents.","date":"2008","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/18178086","citation_count":33,"is_preprint":false},{"pmid":"27583415","id":"PMC_27583415","title":"Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27583415","citation_count":33,"is_preprint":false},{"pmid":"19709640","id":"PMC_19709640","title":"Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.","date":"2009","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/19709640","citation_count":32,"is_preprint":false},{"pmid":"31115486","id":"PMC_31115486","title":"Lysophosphatidic acid induces the migration and invasion of SGC-7901 gastric cancer cells through the LPA2 and Notch signaling pathways.","date":"2019","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31115486","citation_count":30,"is_preprint":false},{"pmid":"23127512","id":"PMC_23127512","title":"Mitigation of radiation injury by selective stimulation of the LPA(2) receptor.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23127512","citation_count":30,"is_preprint":false},{"pmid":"28496416","id":"PMC_28496416","title":"Lysophosphatidic Acid Is Associated with Atherosclerotic Plaque Instability by Regulating NF-κB Dependent Matrix Metalloproteinase-9 Expression via LPA2 in Macrophages.","date":"2017","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28496416","citation_count":29,"is_preprint":false},{"pmid":"32006610","id":"PMC_32006610","title":"Effects of lysophosphatidic acid (LPA) receptor-2 (LPA2) and LPA3 on the regulation of chemoresistance to anticancer drug in lung cancer cells.","date":"2020","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/32006610","citation_count":28,"is_preprint":false},{"pmid":"18501721","id":"PMC_18501721","title":"Regulation of the LPA2 receptor signaling through the carboxyl-terminal tail-mediated protein-protein interactions.","date":"2008","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/18501721","citation_count":24,"is_preprint":false},{"pmid":"22159277","id":"PMC_22159277","title":"LPA stimulates intestinal DRA gene transcription via LPA2 receptor, PI3K/AKT, and c-Fos-dependent pathway.","date":"2011","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22159277","citation_count":24,"is_preprint":false},{"pmid":"32468095","id":"PMC_32468095","title":"Prevention of age-associated neuronal hyperexcitability with improved learning and attention upon knockout or antagonism of LPAR2.","date":"2020","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/32468095","citation_count":21,"is_preprint":false},{"pmid":"26473723","id":"PMC_26473723","title":"Phosphorylation and Internalization of Lysophosphatidic Acid Receptors LPA1, LPA2, and LPA3.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26473723","citation_count":21,"is_preprint":false},{"pmid":"32116549","id":"PMC_32116549","title":"Lysophosphatidic Acid Induces Apoptosis of PC12 Cells Through LPA1 Receptor/LPA2 Receptor/MAPK Signaling Pathway.","date":"2020","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32116549","citation_count":20,"is_preprint":false},{"pmid":"30063964","id":"PMC_30063964","title":"The LPA2 receptor agonist Radioprotectin-1 spares Lgr5-positive intestinal stem cells from radiation injury in murine enteroids.","date":"2018","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/30063964","citation_count":19,"is_preprint":false},{"pmid":"18754873","id":"PMC_18754873","title":"Lysophosphatidic acid stimulates the proliferation and motility of malignant pleural mesothelioma cells through lysophosphatidic acid receptors, LPA1 and LPA2.","date":"2008","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/18754873","citation_count":18,"is_preprint":false},{"pmid":"27134758","id":"PMC_27134758","title":"TRIP6 antagonizes the recruitment of A20 and CYLD to TRAF6 to promote the LPA2 receptor-mediated TRAF6 activation.","date":"2016","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27134758","citation_count":18,"is_preprint":false},{"pmid":"15716590","id":"PMC_15716590","title":"Differential effects of lysolipids on steroid synthesis in cells expressing endogenous LPA2 receptor.","date":"2005","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/15716590","citation_count":17,"is_preprint":false},{"pmid":"32654268","id":"PMC_32654268","title":"LPAR2 receptor activation attenuates radiation-induced disruption of apical junctional complexes and mucosal barrier dysfunction in mouse colon.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32654268","citation_count":16,"is_preprint":false},{"pmid":"37230222","id":"PMC_37230222","title":"Combined inhibition of EZH2 and the autotaxin-LPA-LPA2 axis exerts synergistic antitumor effects on colon cancer cells.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37230222","citation_count":16,"is_preprint":false},{"pmid":"28205098","id":"PMC_28205098","title":"Enhanced cellular functions through induction of LPA2 by cisplatin in fibrosarcoma HT1080 cells.","date":"2017","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28205098","citation_count":16,"is_preprint":false},{"pmid":"34218480","id":"PMC_34218480","title":"LPA2 protein is involved in photosystem II assembly in Chlamydomonas reinhardtii.","date":"2021","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34218480","citation_count":15,"is_preprint":false},{"pmid":"36077141","id":"PMC_36077141","title":"Efficacy Comparison of LPA2 Antagonist H2L5186303 and Agonist GRI977143 on Ovalbumin-Induced Allergic Asthma in BALB/c Mice.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36077141","citation_count":15,"is_preprint":false},{"pmid":"34803427","id":"PMC_34803427","title":"Gintonin regulates inflammation in human IL-1β-stimulated fibroblast-like synoviocytes and carrageenan/kaolin-induced arthritis in rats through LPAR2.","date":"2021","source":"Journal of ginseng research","url":"https://pubmed.ncbi.nlm.nih.gov/34803427","citation_count":14,"is_preprint":false},{"pmid":"33128578","id":"PMC_33128578","title":"Autotaxin stimulates LPA2 receptor in macrophages and exacerbates dextran sulfate sodium-induced acute colitis.","date":"2020","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/33128578","citation_count":13,"is_preprint":false},{"pmid":"36090480","id":"PMC_36090480","title":"Berberine inhibits carcinogenesis through antagonizing the ATX-LPA-LPAR2-p38-leptin axis in a mouse hepatoma model.","date":"2022","source":"Molecular therapy oncolytics","url":"https://pubmed.ncbi.nlm.nih.gov/36090480","citation_count":13,"is_preprint":false},{"pmid":"33841099","id":"PMC_33841099","title":"Dual Role of Lysophosphatidic Acid Receptor 2 (LPA2) in Amyotrophic Lateral Sclerosis.","date":"2021","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33841099","citation_count":13,"is_preprint":false},{"pmid":"25100502","id":"PMC_25100502","title":"Design and synthesis of sulfamoyl benzoic acid analogues with subnanomolar agonist activity specific to the LPA2 receptor.","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25100502","citation_count":12,"is_preprint":false},{"pmid":"28869532","id":"PMC_28869532","title":"CFTR-NHERF2-LPA₂ Complex in the Airway and Gut Epithelia.","date":"2017","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28869532","citation_count":12,"is_preprint":false},{"pmid":"33535610","id":"PMC_33535610","title":"Phosphatidic Acid Stimulates Myoblast Proliferation through Interaction with LPA1 and LPA2 Receptors.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33535610","citation_count":12,"is_preprint":false},{"pmid":"33427061","id":"PMC_33427061","title":"Proximal tubule LPA1 and LPA2 receptors use divergent signaling pathways to additively increase profibrotic cytokine secretion.","date":"2021","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33427061","citation_count":12,"is_preprint":false},{"pmid":"30093116","id":"PMC_30093116","title":"Lysophosphatidic acid receptor-2 (LPA2) and LPA5 regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30093116","citation_count":12,"is_preprint":false},{"pmid":"24613836","id":"PMC_24613836","title":"Structural insights into PDZ-mediated interaction of NHERF2 and LPA(2), a cellular event implicated in CFTR channel regulation.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24613836","citation_count":11,"is_preprint":false},{"pmid":"8988517","id":"PMC_8988517","title":"Direct and modulatory effects of FMRFamide, SKPYMRFamide and acety1-SKPYMRFamide on LPa2, LPa3, and RPa3 identified neurons of Helix lucorum.","date":"1996","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/8988517","citation_count":11,"is_preprint":false},{"pmid":"17952880","id":"PMC_17952880","title":"Alkoxymethylenephosphonate analogues of (Lyso) phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor.","date":"2007","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/17952880","citation_count":10,"is_preprint":false},{"pmid":"32883524","id":"PMC_32883524","title":"Cooperation of G12/13 and Gi proteins via lysophosphatidic acid receptor-2 (LPA2) signaling enhances cancer cell survival to cisplatin.","date":"2020","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/32883524","citation_count":10,"is_preprint":false},{"pmid":"35883686","id":"PMC_35883686","title":"Compensatory Upregulation of LPA2 and Activation of the PI3K-Akt Pathway Prevent LPA5-Dependent Loss of Intestinal Epithelial Cells in Intestinal Organoids.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35883686","citation_count":10,"is_preprint":false},{"pmid":"36551233","id":"PMC_36551233","title":"Alteration of Cellular Energy Metabolism through LPAR2-Axin2 Axis in Gastric Cancer.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36551233","citation_count":9,"is_preprint":false},{"pmid":"29621954","id":"PMC_29621954","title":"LPAR2 and LPAR4 are the Main Receptors Responsible for LPA Actions in Ovarian Endometriotic Cysts.","date":"2018","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/29621954","citation_count":9,"is_preprint":false},{"pmid":"32123645","id":"PMC_32123645","title":"Development and validation of breeder-friendly gene-based markers for lpa1-1 and lpa2-1 genes conferring low phytic acid in maize kernel.","date":"2020","source":"3 Biotech","url":"https://pubmed.ncbi.nlm.nih.gov/32123645","citation_count":9,"is_preprint":false},{"pmid":"32672083","id":"PMC_32672083","title":"Different effects of lysophosphatidic acid receptor-2 (LPA2) and LPA5 on the regulation of chemoresistance in colon cancer cells.","date":"2020","source":"Journal of receptor and signal transduction research","url":"https://pubmed.ncbi.nlm.nih.gov/32672083","citation_count":9,"is_preprint":false},{"pmid":"25542932","id":"PMC_25542932","title":"Asymmetrical macromolecular complex formation of lysophosphatidic acid receptor 2 (LPA2) mediates gradient sensing in fibroblasts.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25542932","citation_count":8,"is_preprint":false},{"pmid":"35948083","id":"PMC_35948083","title":"Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA2), UCM-14216, Ameliorates Spinal Cord Injury in Mice.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35948083","citation_count":7,"is_preprint":false},{"pmid":"33347862","id":"PMC_33347862","title":"Roles of endothelial cells in the regulation of cell motility via lysophosphatidic acid receptor-2 (LPA2) and LPA3 in osteosarcoma cells.","date":"2020","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33347862","citation_count":7,"is_preprint":false},{"pmid":"35151977","id":"PMC_35151977","title":"LPA2 promotes neuronal differentiation and neurite formation in neocortical development.","date":"2022","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/35151977","citation_count":6,"is_preprint":false},{"pmid":"37523658","id":"PMC_37523658","title":"Roles of lysophosphatidic acid (LPA) receptor-2 (LPA2) in the regulation of cellular responses induced by X-ray irradiation and hydrogen peroxide in pancreatic cancer cells.","date":"2023","source":"International journal of radiation biology","url":"https://pubmed.ncbi.nlm.nih.gov/37523658","citation_count":6,"is_preprint":false},{"pmid":"34216604","id":"PMC_34216604","title":"Interplay between LPA2 and LPA3 in LPA-mediated phosphatidylserine cell surface exposure and extracellular vesicles release by erythrocytes.","date":"2021","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34216604","citation_count":6,"is_preprint":false},{"pmid":"15090154","id":"PMC_15090154","title":"Native and recombinant human Edg4 receptor-mediated Ca(2+) signalling.","date":"2002","source":"Assay and drug development technologies","url":"https://pubmed.ncbi.nlm.nih.gov/15090154","citation_count":5,"is_preprint":false},{"pmid":"27124742","id":"PMC_27124742","title":"Transgenic Expression of Human Lysophosphatidic Acid Receptor LPA2 in Mouse Intestinal Epithelial Cells Induces Intestinal Dysplasia.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27124742","citation_count":5,"is_preprint":false},{"pmid":"26687273","id":"PMC_26687273","title":"NT-3 protein levels are enhanced in the hippocampus of PRG1-deficient mice but remain unchanged in PRG1/LPA2 double mutants.","date":"2015","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/26687273","citation_count":5,"is_preprint":false},{"pmid":"33959968","id":"PMC_33959968","title":"BRET analysis reveals interaction between the lysophosphatidic acid receptor LPA2 and the lysophosphatidylinositol receptor GPR55 in live cells.","date":"2021","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/33959968","citation_count":5,"is_preprint":false},{"pmid":"35857125","id":"PMC_35857125","title":"LPAR2-mediated action promotes human renal cell carcinoma via MAPK/NF-κB signaling to regulate cytokine network.","date":"2022","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35857125","citation_count":4,"is_preprint":false},{"pmid":"37816857","id":"PMC_37816857","title":"A dual role of lysophosphatidic acid type 2 receptor (LPAR2) in nonsteroidal anti-inflammatory drug-induced mouse enteropathy.","date":"2023","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/37816857","citation_count":4,"is_preprint":false},{"pmid":"17697599","id":"PMC_17697599","title":"[Expression and significance of Edg4 and Edg7 in the placentas of patients with hypertensive disorder complicating pregnancy].","date":"2007","source":"Zhonghua fu chan ke za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/17697599","citation_count":4,"is_preprint":false},{"pmid":"18379896","id":"PMC_18379896","title":"Full-length coding sequences, polymorphism and chromosomal localizations of the porcine EDG4 and EDG7 genes.","date":"2008","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/18379896","citation_count":3,"is_preprint":false},{"pmid":"38026263","id":"PMC_38026263","title":"LPA2 Alleviates Septic Acute Lung Injury via Protective Endothelial Barrier Function Through Activation of PLC-PKC-FAK.","date":"2023","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/38026263","citation_count":3,"is_preprint":false},{"pmid":"35799024","id":"PMC_35799024","title":"Estrogen-increased SGK1 Promotes Endometrial Stromal Cell Invasion in Adenomyosis by Regulating with LPAR2.","date":"2022","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/35799024","citation_count":2,"is_preprint":false},{"pmid":"39125747","id":"PMC_39125747","title":"Lysophosphatidic Acid Receptors LPAR5 and LPAR2 Inversely Control Hydroxychloroquine-Evoked Itch and Scratching in Mice.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39125747","citation_count":1,"is_preprint":false},{"pmid":"38986295","id":"PMC_38986295","title":"Circ_0007611 modulates the miR-34c-5p/LPAR2 cascade to suppress proliferation and enhance apoptosis of HTR-8/SVneo cells.","date":"2024","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/38986295","citation_count":1,"is_preprint":false},{"pmid":"37758013","id":"PMC_37758013","title":"Differential targeting of lysophosphatidic acid LPA1, LPA2, and LPA3 receptor signalling by tricyclic and tetracyclic antidepressants.","date":"2023","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37758013","citation_count":1,"is_preprint":false},{"pmid":"41454227","id":"PMC_41454227","title":"Inhibition of autotaxin sensitizes colon cancer to radiation by suppressing LPAR2-AKT survival signaling.","date":"2025","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/41454227","citation_count":1,"is_preprint":false},{"pmid":"38368704","id":"PMC_38368704","title":"A mutation in LPAR2 activates the miR-939-5p-LPAR2-PI3K/AKT axis to regulate the proliferation and apoptosis of granulosa cells in sheep.","date":"2024","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/38368704","citation_count":1,"is_preprint":false},{"pmid":"41138698","id":"PMC_41138698","title":"Spatiotemporal expression of lpa1 and lpa2 genes showed low phytate accumulation in maize foliage and seeds during early developmental stages.","date":"2025","source":"Plant physiology and biochemistry : PPB","url":"https://pubmed.ncbi.nlm.nih.gov/41138698","citation_count":1,"is_preprint":false},{"pmid":"38615508","id":"PMC_38615508","title":"Regulation of cellular responses to X-ray irradiation through the activation of lysophosphatidic acid (LPA) receptor-3 (LPA3) and LPA2 in osteosarcoma cells.","date":"2024","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/38615508","citation_count":0,"is_preprint":false},{"pmid":"41476039","id":"PMC_41476039","title":"Engineering Native-like GPCR Antigens Enables Discovery of an LPA2-Blocking Antibody for Ovarian Cancer.","date":"2025","source":"ACS synthetic biology","url":"https://pubmed.ncbi.nlm.nih.gov/41476039","citation_count":0,"is_preprint":false},{"pmid":"41418976","id":"PMC_41418976","title":"The LPA2 receptor PDZ domain affects canonical Wnt signaling in colon cancer cells.","date":"2025","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/41418976","citation_count":0,"is_preprint":false},{"pmid":"18307905","id":"PMC_18307905","title":"[Vector construction and silencing effect of Edg4 gene targeted small interfering RNA in ovarian cancer cell line].","date":"2007","source":"Zhonghua fu chan ke za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/18307905","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.21.644686","title":"Redirecting cytotoxic lymphocytes to breast cancer tumors via metabolite-sensing receptors","date":"2025-03-25","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.21.644686","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51082,"output_tokens":7453,"usd":0.132521},"stage2":{"model":"claude-opus-4-6","input_tokens":11333,"output_tokens":4165,"usd":0.241185},"total_usd":0.373706,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"LPA2 (EDG4/LP(A2)) couples to multiple G-proteins and mediates LPA-dependent inositol phosphate production, MAPK activation, arachidonic acid release, and inhibition of forskolin-induced cAMP accumulation in neuronal cell lines; LPA2 expression induces cell rounding in neuroblastoma cells.\",\n      \"method\": \"Retrovirus-mediated heterologous expression in B103 neuroblastoma cells lacking endogenous LPA receptors, followed by functional signaling assays\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — clean reconstitution system (receptor-null cells), multiple orthogonal signaling readouts\",\n      \"pmids\": [\"11040035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In human SH-SY5Y neuroblastoma cells, LPA2 (Edg-4) mediates Ca2+ mobilization via production of intracellular sphingosine 1-phosphate (S1P) through sphingosine kinase, independent of Ins(1,4,5)P3 receptor-mediated Ca2+ release, with subsequent interaction between the S1P pathway and IP3 receptors.\",\n      \"method\": \"Pharmacological inhibition of sphingosine kinase, 45Ca2+ release assays in permeabilized cells, confocal microscopy of Ca2+ puffs, [3H]S1P production measurement\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (metabolite measurement, Ca2+ imaging, permeabilized cell assay) in cells with endogenous Edg-4\",\n      \"pmids\": [\"10954727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"LPA2 acts redundantly with LPA1 to mediate most LPA responses in fibroblasts, including phospholipase C activation, Ca2+ mobilization, adenylyl cyclase activation, proliferation, JNK activation, Akt activation, and stress fiber formation, as demonstrated in lpa1(-/-)/lpa2(-/-) double-knockout mouse embryonic fibroblasts.\",\n      \"method\": \"Genetic knockout (lpa2-/- and lpa1-/-/lpa2-/- mice), MEF functional assays for PLC, Ca2+, cAMP, proliferation, JNK, Akt, and cytoskeletal responses\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with multiple orthogonal signaling readouts, replicated across receptor combinations\",\n      \"pmids\": [\"12215548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"LPA2 specifically interacts via its C-terminal PDZ-binding motif with the second PDZ domain of NHERF2, which scaffolds a ternary complex (LPA2–NHERF2–PLC-β3), thereby specifically potentiating LPA-induced PLC-β3 activation and downstream ERK activation leading to COX-2 induction.\",\n      \"method\": \"Co-immunoprecipitation, PDZ-binding motif mutagenesis, RNA interference of NHERF2 and PLC-β3 isoforms, stable expression in HEK293 cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal interactions confirmed, mutagenesis of binding motif, isoform-specific RNAi, multiple signaling readouts\",\n      \"pmids\": [\"15143197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"In human colon cancer cells, LPA2 activates Akt via Gi-protein and ERK1/2 via PLCβ, and mediates IL-8 synthesis; LPA2 directly interacts with NHERF2, which is required for efficient Akt and ERK1/2 activation.\",\n      \"method\": \"Pertussis toxin inhibition, PLCβ inhibitor (U-73122), Co-IP of LPA2 and NHERF2, NHERF2 siRNA knockdown, LPA2 siRNA\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection of G-protein coupling, Co-IP, and RNAi in endogenous context\",\n      \"pmids\": [\"15728708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"LPA2 mediates Rho-dependent chemotaxis in breast cancer cells with lower efficacy than LPA1; LPA2 specifically activates RhoA to promote cell migration, as demonstrated by LPA2-specific siRNA and C3 exotransferase treatment in BT-20 cells.\",\n      \"method\": \"LPA2-specific siRNA, C3 exotransferase (RhoA inhibitor), LPA1 exogenous expression, Ki16425 antagonist, Transwell chemotaxis assay\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific knockdown combined with RhoA inhibition and rescue experiments\",\n      \"pmids\": [\"17496233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"LPA2 C-terminal tail contains at least two protein interaction motifs mediating PDZ-protein interactions (e.g., NHERF2, MAGI-3) and zinc finger protein interactions (e.g., TRIP6), which regulate the specificity and efficiency of LPA2-mediated signaling.\",\n      \"method\": \"Review/summary of biochemical protein-protein interaction studies (Co-IP, PDZ binding motif mapping)\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — synthesis review citing multiple interaction studies\",\n      \"pmids\": [\"18501721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LPA-induced αvβ6 integrin-mediated TGF-β activation in epithelial cells is mediated specifically via LPA2 receptor signaling through Gαq, RhoA, and Rho kinase.\",\n      \"method\": \"LPA2-specific siRNA knockdown, Gαq pathway inhibition, RhoA and Rho kinase inhibitors, TGF-β bioassay in human bronchial epithelial cells\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific knockdown, pathway dissection with multiple inhibitors, functional TGF-β activation readout\",\n      \"pmids\": [\"19147812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LPA2 couples to the G12/13/Rho signaling pathway (not Gi) to inhibit EGF-induced migration and invasion of pancreatic cancer cells, contrasting with LPA1-mediated stimulation of migration.\",\n      \"method\": \"LPA2-specific siRNA, pertussis toxin (Gi inhibitor), LP-105 LPA2-specific agonist, RhoA-dominant negative and C3 toxin, Transwell and Matrigel invasion assays\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific knockdown, pathway-specific agonist, multiple GTPase inhibitors across multiple cell lines\",\n      \"pmids\": [\"19129242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LPA2 absence reduces colon tumor formation by attenuating epithelial proliferation and decreasing β-catenin, KLF5, COX-2 expression, and macrophage infiltration via monocyte chemoattractant protein-1 and macrophage migration inhibitory factor.\",\n      \"method\": \"LPA2 knockout mice in azoxymethane/DSS colitis-associated cancer model, LPA treatment in Apc(min/+) mice, IHC and molecular marker analysis\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with defined mechanistic readouts in validated in vivo cancer model\",\n      \"pmids\": [\"19328876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"MAGI-3 competes with NHERF-2 for binding to LPA2 and PLC-β3: MAGI-3 binding shifts G-protein coupling toward Gα12 (inhibitory signaling), while NHERF-2 promotes Gαq coupling (stimulatory PLC signaling), thereby opposing effects on LPA2-mediated migration, invasion, and NF-κB activation.\",\n      \"method\": \"Co-IP of LPA2 with MAGI-3, NHERF-2, Gα12, Gαq; MAGI-3 overexpression and knockdown; inositol phosphate production assay; cell migration and invasion assays in HCT116 and SW480\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP, gain- and loss-of-function, multiple functional readouts, competition mechanism demonstrated\",\n      \"pmids\": [\"21134377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LPA stimulates DRA (SLC26A3) gene transcription through the LPA2 receptor via a PI3K/AKT and c-Fos-dependent pathway acting on the -1183/-790 region of the DRA promoter.\",\n      \"method\": \"LPA2 siRNA knockdown, PI3K inhibitor, DRA promoter deletion constructs/reporter assays, EMSA, c-Fos overexpression and siRNA in Caco-2 cells\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific knockdown, promoter mapping, EMSA, transcription factor overexpression/knockdown\",\n      \"pmids\": [\"22159277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LPA2 mediates proximal tubule cell secretion of PDGF-B and CTGF through Gαq, Rho/Rho-kinase, and αvβ6 integrin-dependent transactivation of latent TGF-β, which then activates SMAD signaling to upregulate these profibrotic cytokines.\",\n      \"method\": \"LPA2 siRNA, Gαq inhibition, Rho/ROCK inhibitors, αvβ6 integrin blocking antibody, TGF-β bioassays, SMAD signaling analysis, ischemia-reperfusion injury rat model\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific knockdown, multi-level pathway inhibition, in vitro and in vivo concordance\",\n      \"pmids\": [\"22885106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"LPA2 activation promotes an antiapoptotic signaling complex comprising LPA2, NHERF2, and TRIP6 (thyroid receptor interacting protein 6); non-lipid LPA2-specific agonist GRI977143 assembles this complex and activates ERK1/2 prosurvival signaling, reducing caspase activation and DNA fragmentation.\",\n      \"method\": \"Co-IP of LPA2–NHERF2–TRIP6 complex, MEF cells from LPA1&2-DKO reconstituted with LPA2, caspase activity assays, PARP cleavage, DNA fragmentation, ERK1/2 phosphorylation\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reconstituted receptor-null system, complex formation by Co-IP, multiple apoptosis readouts, LPA2-specific agonist\",\n      \"pmids\": [\"22968304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LPA2 mediates collective cell migration of neural crest cells in vivo by promoting N-cadherin internalization downstream of LPA, reducing cell-cell adhesion and increasing tissue fluidity to allow a solid-to-fluid-like transition while maintaining collective behavior.\",\n      \"method\": \"In vivo neural crest imaging (Xenopus), LPA2 inhibition/knockdown, N-cadherin trafficking assays, rheological analysis of tissue fluidity\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined cellular mechanism (cadherin internalization) and biophysical readout in vivo\",\n      \"pmids\": [\"25002680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LPA2 forms spatiotemporally restricted, asymmetric macromolecular complexes via PDZ motif-mediated interactions at the leading edge of chemotacting fibroblasts, triggering localized Ca2+ puff gradients that govern gradient sensing and directional migration toward LPA.\",\n      \"method\": \"Single-particle tracking of LPA2 mobility, PDZ motif mutagenesis, Ca2+ imaging, directional migration assays in fibroblasts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — single-particle tracking + mutagenesis + functional Ca2+ and migration readouts\",\n      \"pmids\": [\"25542932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Crystal structure of NHERF2 PDZ1 domain in complex with the C-terminal LPA2 peptide reveals that binding specificity is achieved through hydrogen bonds and hydrophobic contacts with the last four LPA2 residues, and identifies a small surface pocket adjacent to the binding site.\",\n      \"method\": \"X-ray crystallography of NHERF2 PDZ1–LPA2 C-terminal peptide complex\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with atomic resolution of the interaction interface\",\n      \"pmids\": [\"24613836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The autotaxin-LPA2 axis is upregulated by γ-irradiation via an ATM/NF-κB-dependent mechanism; LPA2 activation accelerates DNA damage repair (resolution of γ-H2AX) through ERK1/2 and PI3K/AKT pathways, and the C-terminus of LPA2 (C311A/C314A/L351A mutation) is required for this effect.\",\n      \"method\": \"qRT-PCR, NF-κB site mutagenesis in lpa2 promoter, ATM/ATR kinase inhibitor (CGK-733), γ-H2AX kinetics in LPA2-reconstituted MEF cells, pertussis toxin, C-terminal LPA2 mutagenesis, Lpar2 KO mice irradiation model\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter mutagenesis, receptor mutagenesis, reconstituted system, in vivo KO confirmation\",\n      \"pmids\": [\"26027517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRIP6 functions as a positive regulator of LPA2-induced NF-κB and JNK signaling by directly binding and activating the E3 ligase TRAF6 upon LPA stimulation; TRIP6 antagonizes recruitment of deubiquitinases A20 and CYLD to TRAF6, sustaining its E3 ligase activity. Conversely, TRAF6 promotes TRIP6 phosphorylation by c-Src and its binding to NF-κB p65.\",\n      \"method\": \"Co-IP of TRIP6–TRAF6–LPA2, TRIP6 shRNA and CRISPR/sgRNA knockdown, TRAF6 siRNA, overexpression assays, NF-κB and JNK/p38 activation assays in ovarian cancer cells\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP of complex components, multiple loss-of-function approaches, mechanistic dissection of ubiquitin pathway\",\n      \"pmids\": [\"27134758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"LPA2 forms a macromolecular complex with CFTR and NHERF2 at the apical plasma membrane of airway and gut epithelial cells; disruption of the PDZ-mediated NHERF2–LPA2 interaction abolishes the LPA inhibitory effect on CFTR Cl- channel activity.\",\n      \"method\": \"Co-IP, PDZ motif disruption, CFTR channel activity measurements (reviewed with prior functional data)\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review synthesizing prior Co-IP and functional data from multiple papers\",\n      \"pmids\": [\"28869532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LPA2 mediates LPA-induced ovarian cancer cell migration via phosphorylation of ERM (ezrin/radixin/moesin) proteins at their C-termini through the Gα12/13/RhoA pathway; gene silencing of LPA2 or expression of dominant-negative ezrin completely abolishes LPA-induced migration.\",\n      \"method\": \"LPA receptor siRNA knockdown, Gα pathway inhibitors, ERM phosphorylation western blot, dominant-negative ezrin-T567A overexpression, Transwell migration assay in OVCAR-3 cells\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific knockdown, pathway dissection, dominant-negative functional rescue\",\n      \"pmids\": [\"29329782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LPA2 receptor agonism reduces γ-irradiation-induced disruption of colonic epithelial tight junction proteins via a Rho-kinase-dependent mechanism, protecting mucosal barrier function and reducing endotoxemia; Lpar2-/- mice show more severe TJ disruption after irradiation than wild-type mice.\",\n      \"method\": \"Lpar2 KO mice, LPA2 agonist RP1 (Radioprotectin-1), ROCK inhibitor, immunofluorescence of TJ proteins, mucosal permeability (inulin), plasma LPS measurement, actin cytoskeleton imaging\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO and pharmacological agonism, pathway inhibition, multiple functional readouts in vitro and in vivo\",\n      \"pmids\": [\"32654268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LPA2 receptor activation promotes endothelial cell proliferation through PI3K-Akt/PLC-Raf1-Erk signaling and enhances tube formation via PKD1-CD36 signaling; endothelial-specific LPA2 knockout phenocopies global knockout in cardiac ischemia, establishing LPA2 as the relevant LPA receptor in cardiac endothelial cells after MI.\",\n      \"method\": \"Global and endothelial-specific Lpar2 KO mice, adenovirus-mediated Lpar2 overexpression, pharmacological LPA2 activation, MI models (adult and neonatal), PI3K/Akt/PLC/ERK pathway inhibition, tube formation assays\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell type-specific KO phenocopy, adenoviral rescue, multiple signaling pathway readouts, in vivo and in vitro concordance\",\n      \"pmids\": [\"35920162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Proximal tubule LPA1 and LPA2 receptors use divergent signaling pathways (LPA2 via Gαq-αvβ6-TGF-β1/SMAD; LPA1 via EGFR-ERK1/2-AP-1) that additively increase PDGF-B and CTGF production; autotaxin inhibition suppresses both pathways.\",\n      \"method\": \"Pathway-specific inhibitors for each arm, autotaxin inhibitor, dual receptor knockdown/inhibition, SMAD and ERK signaling readouts in proximal tubule cells and IRI kidneys\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pathway-specific dissection of two receptors with convergent functional output, in vitro and in vivo concordance\",\n      \"pmids\": [\"33427061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Endothelial LPA2 protects vascular barrier function in septic ALI through the PLC-PKC-FAK signaling pathway, maintaining tight junction (ZO-1, claudin-5) and adherens junction (VE-cadherin) protein expression.\",\n      \"method\": \"Lpar2 KO mice (LPS-induced sepsis model), DBIBB LPA2 agonist, transendothelial electrical resistance (TEER), Evans blue dye permeability, Western blot of junction proteins, PLC/PKC/FAK pathway analysis in MLMECs\",\n      \"journal\": \"Journal of inflammation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO and pharmacological agonism, defined signaling pathway, multiple functional endothelial barrier readouts\",\n      \"pmids\": [\"38026263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LPA2 interacts via its PDZ-binding motif in its carboxyl terminus with Dishevelled proteins Dvl2 and Dvl3 in colon cancer cells, co-activating canonical Wnt/β-catenin signaling (S552 and S675 phosphorylation, β-catenin transcriptional activity) in a non-additive manner with Wnt-3a; mutation of the LPA2 PDZ motif (LPA2-PDZminus) disrupts this interaction and impairs canonical Wnt signaling activation.\",\n      \"method\": \"Co-immunoprecipitation of LPA2 with Dvl2/Dvl3, LPA2-PDZminus mutant expression, β-catenin reporter assay, phospho-β-catenin Western blot, cell migration and proliferation assays\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP demonstrating physical interaction, PDZ motif mutagenesis with functional consequence on Wnt signaling\",\n      \"pmids\": [\"41418976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LPA2 receptor phosphorylation requires higher concentrations of LPA or PKC activators than LPA1/LPA3, and its internalization is less intense; homologous desensitization of LPA2 occurs independently of PKC. LPA2-mediated ERK1/2 phosphorylation involves EGF receptor transactivation.\",\n      \"method\": \"Stably expressed LPA1, LPA2, LPA3 in C9 cells; phorbol ester (PMA) and bisindolylmaleimide I treatment; PKC down-regulation; EGFR tyrosine kinase inhibitor; intracellular Ca2+ assay; ERK phosphorylation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological tools in heterologous expression system, but single lab with one system\",\n      \"pmids\": [\"26473723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LPA2 signaling in macrophages mediates ATX/LPA-induced pro-inflammatory cytokine production; LPA2 gene silencing in RAW264.7 macrophages reduces inflammatory cytokine output, and adenoviral lpa2 shRNA delivery ameliorates DSS-induced colitis in mice.\",\n      \"method\": \"LPA2 siRNA in RAW264.7 and BMDM, adenoviral lpa2 shRNA in DSS colitis mouse model, cytokine ELISA, qRT-PCR of LPA2 expression\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific knockdown in vitro and in vivo, but mechanistic pathway detail limited\",\n      \"pmids\": [\"33128578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LPA2 mediates LPA-induced migration and invasion of gastric cancer cells through activation of Notch1 signaling and PI3K/AKT phosphorylation; LPA2 physically interacts with Notch1 as shown by co-immunoprecipitation.\",\n      \"method\": \"LPA2 and Notch1 siRNA knockdown, Transwell migration/invasion assays, immunoprecipitation of LPA2-Notch1 complex, EMT marker analysis in SGC-7901 cells\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP plus functional knockdown, but novel interaction without structural validation\",\n      \"pmids\": [\"31115486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LPA2 interacts with GPR55 in live cells (BRET analysis); co-activation of LPA2 and GPR55 leads to co-internalization, synergistic reduction in intracellular cAMP, and synergistic promotion of cell proliferation and cancer gene expression.\",\n      \"method\": \"BRET (bioluminescence resonance energy transfer) in live cells, co-internalization imaging, cAMP measurement, cell proliferation assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — BRET demonstrates physical proximity in live cells, functional co-activation readouts, but single lab study\",\n      \"pmids\": [\"33959968\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LPAR2 is a Gαi-, Gαq-, and Gα12/13-coupling GPCR for lysophosphatidic acid whose signaling specificity and efficiency are determined by a C-terminal PDZ-binding motif that scaffolds context-dependent macromolecular complexes (with NHERF2–PLC-β3, MAGI-3, TRIP6–TRAF6, and Dvl2/Dvl3), activating downstream pathways including PLC-β/Ca2+/IP3, PI3K-Akt, ERK1/2, RhoA, and NF-κB to mediate cell survival, migration, cytoskeletal reorganization, epithelial barrier maintenance, TGF-β transactivation via αvβ6 integrin, DNA damage repair, and Wnt signaling, while also acting as a radioprotective and anti-apoptotic receptor whose lpa2 gene is itself a DNA-damage-response gene transcriptionally upregulated by ATM via NF-κB.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LPAR2 (LPA2/EDG4) is a lysophosphatidic acid receptor that couples to Gαi, Gαq, and Gα12/13 to activate PLC-β/Ca²⁺, PI3K-Akt, ERK1/2, RhoA, NF-κB, and Wnt/β-catenin signaling, thereby regulating cell survival, proliferation, migration, cytoskeletal dynamics, and epithelial/endothelial barrier integrity [PMID:11040035, PMID:12215548, PMID:25002680, PMID:32654268, PMID:38026263]. Signaling specificity is determined by a C-terminal PDZ-binding motif that recruits context-dependent scaffolding partners — NHERF2 promotes Gαq/PLC-β3 coupling and ERK activation, MAGI-3 redirects coupling toward Gα12 to oppose NHERF2-driven responses, and TRIP6 activates TRAF6-dependent NF-κB signaling — while interaction with Dvl2/Dvl3 co-activates canonical Wnt signaling [PMID:15143197, PMID:21134377, PMID:27134758, PMID:41418976]. LPA2 also functions as a radioprotective receptor: its gene is transcriptionally upregulated by γ-irradiation via ATM/NF-κB, and its activation accelerates DNA damage repair and preserves tight junction integrity through Rho-kinase-dependent mechanisms [PMID:26027517, PMID:32654268]. In vivo, LPA2 loss reduces colitis-associated colon tumorigenesis by attenuating β-catenin, COX-2, and macrophage infiltration, while endothelial-specific deletion impairs cardiac angiogenesis after myocardial infarction [PMID:19328876, PMID:35920162].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing that LPA2 is a functional multi-pathway GPCR resolved which signaling outputs this receptor activates, demonstrating coupling to PLC/IP production, MAPK, arachidonic acid release, cAMP inhibition, and Ca²⁺ mobilization.\",\n      \"evidence\": \"Heterologous expression in receptor-null B103 neuroblastoma cells and Ca²⁺/sphingosine kinase assays in SH-SY5Y cells\",\n      \"pmids\": [\"11040035\", \"10954727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of individual G-protein subtypes not resolved\", \"No structural information on receptor-G-protein coupling\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Genetic ablation of Lpar1 and Lpar2 in mouse fibroblasts demonstrated functional redundancy between LPA1 and LPA2 for most LPA responses, defining LPA2 as necessary for full LPA signaling when LPA1 is absent.\",\n      \"evidence\": \"Lpa1⁻/⁻/lpa2⁻/⁻ double-knockout MEFs with multiple signaling readouts\",\n      \"pmids\": [\"12215548\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor-specific versus shared downstream effectors not delineated\", \"In vivo phenotype of lpa2 single knockout not yet characterized\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Discovery of the NHERF2–LPA2–PLC-β3 ternary complex identified the PDZ-binding motif as the molecular determinant of LPA2 signaling specificity, explaining how a broadly coupled GPCR achieves selective effector activation.\",\n      \"evidence\": \"Co-IP, PDZ motif mutagenesis, and isoform-specific RNAi in HEK293 cells\",\n      \"pmids\": [\"15143197\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and dynamics of the ternary complex unknown\", \"Whether other PDZ scaffold proteins compete for this motif not yet tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Receptor-specific knockdown established that LPA2 activates RhoA to drive breast cancer cell chemotaxis, distinguishing its migration mechanism from LPA1 and revealing G12/13-RhoA as an LPA2-selective pathway arm.\",\n      \"evidence\": \"LPA2 siRNA, C3 exotransferase, and Transwell assays in BT-20 cells\",\n      \"pmids\": [\"17496233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RhoGEF linking LPA2 to RhoA not identified\", \"Context-dependence of LPA2 promoting versus inhibiting migration not explained\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Three contemporaneous studies revealed LPA2's diverse in vivo roles: Gαq/RhoA-dependent TGF-β transactivation via αvβ6 integrin in epithelia, G12/13-dependent suppression of EGF-induced migration in pancreatic cancer, and promotion of colon tumorigenesis through β-catenin/COX-2 in knockout mice.\",\n      \"evidence\": \"Receptor-specific siRNA with pathway inhibitors in bronchial/pancreatic cells; Lpar2⁻/⁻ mice in AOM/DSS colon cancer model\",\n      \"pmids\": [\"19147812\", \"19129242\", \"19328876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How LPA2 promotes migration in one context but inhibits it in another remains mechanistically unresolved\", \"Direct targets linking LPA2 to β-catenin stabilization not identified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The discovery that MAGI-3 competes with NHERF2 for the LPA2 PDZ motif and shifts G-protein coupling from Gαq toward Gα12 established a scaffold-switching model for bidirectional regulation of LPA2 signaling.\",\n      \"evidence\": \"Co-IP competition experiments, MAGI-3 overexpression/knockdown with signaling readouts in colon cancer cells\",\n      \"pmids\": [\"21134377\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"What determines the relative abundance of MAGI-3 versus NHERF2 at the receptor in different tissues\", \"Whether scaffold switching occurs dynamically in real time\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of the LPA2–NHERF2–TRIP6 antiapoptotic complex and demonstration of LPA2-mediated TGF-β/SMAD-dependent fibrotic signaling in kidney established dual pro-survival and pro-fibrotic effector arms downstream of LPA2.\",\n      \"evidence\": \"Co-IP in reconstituted LPA1/2-DKO MEFs with LPA2-specific agonist GRI977143; pathway dissection with ROCK/Gαq inhibitors in proximal tubule cells and IRI rat model\",\n      \"pmids\": [\"22968304\", \"22885106\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TRIP6 is recruited to LPA2 (direct or NHERF2-bridged) not fully resolved\", \"Whether the antiapoptotic complex operates in non-epithelial cell types unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Single-particle tracking and in vivo neural crest imaging revealed that LPA2 PDZ-dependent complexes are spatially polarized at the leading edge, generating asymmetric Ca²⁺ gradients for chemotaxis and driving N-cadherin internalization for collective cell migration.\",\n      \"evidence\": \"Single-particle tracking with PDZ mutagenesis in fibroblasts; LPA2 knockdown in Xenopus neural crest with rheological analysis\",\n      \"pmids\": [\"25542932\", \"25002680\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the PDZ scaffold at the leading edge not determined\", \"How N-cadherin internalization is mechanistically linked to LPA2 downstream signaling not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Crystal structure of NHERF2-PDZ1 bound to the LPA2 C-terminal peptide provided atomic-level understanding of the specificity determinants, revealing hydrogen-bonding and hydrophobic contacts and a druggable surface pocket.\",\n      \"evidence\": \"X-ray crystallography of NHERF2 PDZ1–LPA2 peptide complex\",\n      \"pmids\": [\"24613836\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full-length LPA2 structure in complex with NHERF2\", \"Whether the adjacent pocket is functionally exploitable not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstration that LPA2 is a DNA damage-response gene transcriptionally induced by γ-irradiation through ATM/NF-κB, and that LPA2 activation accelerates γ-H2AX resolution via ERK/PI3K-Akt, established a feed-forward radioprotective circuit dependent on the C-terminal interaction motif.\",\n      \"evidence\": \"LPA2 promoter NF-κB site mutagenesis, ATM inhibitor, γ-H2AX kinetics in LPA2-reconstituted MEFs, Lpar2 KO mice irradiation\",\n      \"pmids\": [\"26027517\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct DNA repair effectors downstream of ERK/Akt in this context not identified\", \"Whether this radioprotective mechanism operates in non-intestinal tissues not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mechanistic dissection of the TRIP6–TRAF6 axis showed TRIP6 sustains LPA2-induced NF-κB signaling by activating TRAF6 E3 ligase activity and antagonizing deubiquitinases A20/CYLD, providing the molecular logic for how the LPA2 C-terminal scaffold drives inflammatory gene expression.\",\n      \"evidence\": \"Co-IP, CRISPR knockout, and shRNA knockdown of TRIP6/TRAF6 with NF-κB/JNK readouts in ovarian cancer cells\",\n      \"pmids\": [\"27134758\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin chain types on TRAF6 in LPA2 context not defined\", \"Whether TRIP6-TRAF6 engagement is unique to LPA2 or shared with other GPCRs\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Pharmacological agonism and genetic ablation of LPA2 established its role in maintaining epithelial tight junctions after irradiation via Rho-kinase, and in macrophage-mediated inflammation during colitis, broadening its barrier-protective and immunomodulatory functions.\",\n      \"evidence\": \"Lpar2 KO mice with RP1 agonist in irradiation model; LPA2 siRNA in macrophages and adenoviral shRNA in DSS colitis model\",\n      \"pmids\": [\"32654268\", \"33128578\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which tight junction proteins are direct versus indirect targets of Rho-kinase in this context\", \"Macrophage-specific signaling pathway downstream of LPA2 not detailed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Endothelial-specific Lpar2 knockout phenocopied global knockout in cardiac ischemia, establishing LPA2 as the functionally relevant LPA receptor in cardiac endothelium where it drives angiogenesis through PI3K-Akt/PLC-Raf1-Erk and PKD1-CD36 pathways.\",\n      \"evidence\": \"Endothelial-specific and global Lpar2 KO, adenoviral rescue, MI models in adult and neonatal mice\",\n      \"pmids\": [\"35920162\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PKD1-CD36 signaling mechanistically connects to tube formation not defined\", \"Whether LPA2 agonism is therapeutic post-MI not tested in preclinical intervention studies\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"LPA2 was shown to protect endothelial barrier function in sepsis through PLC-PKC-FAK signaling that maintains tight and adherens junction proteins, extending the barrier-protective role from epithelial to endothelial contexts.\",\n      \"evidence\": \"Lpar2 KO mice in LPS-sepsis model, DBIBB agonist, TEER, Evans blue permeability, junction protein analysis in MLMECs\",\n      \"pmids\": [\"38026263\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FAK is directly phosphorylated by PKC or through an intermediate kinase\", \"Endothelial scaffold complex identity (NHERF2 or other) not determined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovery of a PDZ-dependent LPA2–Dvl2/Dvl3 interaction that co-activates canonical Wnt/β-catenin signaling provided a molecular mechanism for the earlier observation that LPA2 loss reduces β-catenin in colon tumors.\",\n      \"evidence\": \"Co-IP of LPA2 with Dvl2/Dvl3, PDZ-minus mutant, β-catenin reporter and phospho-β-catenin analysis in colon cancer cells\",\n      \"pmids\": [\"41418976\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LPA2-Dvl interaction occurs through direct PDZ-PDZ binding or requires a bridging scaffold\", \"Functional consequence of LPA2-Wnt crosstalk in vivo not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A full-length structure of LPA2 in complex with its C-terminal scaffolding partners is lacking, and the rules governing scaffold selection (NHERF2 vs MAGI-3 vs TRIP6 vs Dvl) in different tissue contexts remain undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full-length LPA2 cryo-EM or crystal structure with scaffold bound\", \"Tissue-specific determinants of scaffold partner selection unknown\", \"Therapeutic window for LPA2 agonism (radioprotection/barrier) versus antagonism (cancer) not delineated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [15, 19, 24]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 3, 4, 7, 8, 10, 17, 20, 22, 24, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 9, 28]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [13, 17]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [14, 21, 24]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"complexes\": [\n      \"LPA2–NHERF2–PLC-β3\",\n      \"LPA2–NHERF2–TRIP6\",\n      \"TRIP6–TRAF6\"\n    ],\n    \"partners\": [\n      \"NHERF2\",\n      \"MAGI-3\",\n      \"TRIP6\",\n      \"TRAF6\",\n      \"DVL2\",\n      \"DVL3\",\n      \"PLC-β3\",\n      \"CFTR\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}